<?xml version="1.0" encoding="utf-8"?>
<doi_batch xmlns="http://www.crossref.org/schema/4.3.6" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:jats="http://www.ncbi.nlm.nih.gov/JATS1" xmlns:ai="http://www.crossref.org/AccessIndicators.xsd" version="4.3.6" xsi:schemaLocation="http://www.crossref.org/schema/4.3.6 https://www.crossref.org/schemas/crossref4.3.6.xsd">
  <head>
    <doi_batch_id>_1630693387</doi_batch_id>
    <timestamp>1630693387</timestamp>
    <depositor>
      <depositor_name>brea</depositor_name>
      <email_address>akaviani@archbreastcancer.com</email_address>
    </depositor>
    <registrant>Farname Inc</registrant>
  </head>
  <body>
    <journal>
      <journal_metadata>
        <full_title>Archives of Breast Cancer</full_title>
        <abbrev_title>Arch Breast Cancer</abbrev_title>
        <issn media_type="electronic">2383-0433</issn>
      </journal_metadata>
      <journal_issue>
        <publication_date media_type="online">
          <month>07</month>
          <day>28</day>
          <year>2021</year>
        </publication_date>
      </journal_issue>
      <journal_article xmlns:jats="http://www.ncbi.nlm.nih.gov/JATS1" xmlns:ai="http://www.crossref.org/AccessIndicators.xsd" publication_type="full_text" metadata_distribution_opts="any">
        <titles>
          <title>Marine Cyclic Dipeptide Cyclo (L-Leu-L-Pro) Protects Normal Breast  Epithelial Cells from tBHP-induced Oxidative Damage by Targeting CD151</title>
        </titles>
        <contributors>
          <person_name contributor_role="author" sequence="first" language="en">
            <given_name>Deepak</given_name>
            <surname>KGK</surname>
          </person_name>
          <person_name contributor_role="author" sequence="additional" language="en">
            <given_name>Seema</given_name>
            <surname>Kumari</surname>
          </person_name>
          <person_name contributor_role="author" sequence="additional" language="en">
            <given_name>Rama Rao</given_name>
            <surname>Malla</surname>
          </person_name>
        </contributors>
        <jats:abstract xmlns:jats="http://www.ncbi.nlm.nih.gov/JATS1">
          <jats:p>Background: Oxidative stress plays a key role in breast carcinogenesis. Cyclo (L-Leu-L-Pro) (CLP) is a homodetic cyclic dipeptide with 2,5-diketopiperazine scaffold isolated from marine actinobacteria. This study aimed to evaluate the protective activity of CLP and linear - (L-Leu-L-Pro) (LP) from tert-butyl hydroperoxide (tBHP)-induced damage using normal breast epithelial cell line model (MCF-12A). Methods: The cytoprotective activity was evaluated by detecting the changes in intracellular ROS, mitochondrial superoxide, hydroxyl radical, hydrogen peroxide, and lipid peroxidation detection assays as well as cytotoxic assays of MTT, LDH assays and phase contrast microscopy. Genoprotective activity was evaluated by (Apurinic/Apyrimidinic) AP site, alkaline Comet, and 8-hydroxy-2-deoxyguanosine assays. Results: The marine cyclic peptide, CLP, significantly protected MCF-12A cells by scavenging tBHP induced intracellular ROS such as super oxide, hydroxyl radicals and hydrogen peroxide, and by reducing the cytotoxicity and genotoxicity effect compared to LP. Moreover, the results showed that CD151 gene silencing by shRNA significantly reduced the overexpression of CD151, tBHP-induced ROS generation, cytotoxicity and genotoxicity in MCF-12A cells. The overexpression of CD151 caused increased levels of cytochrome P450, but was reduced following the application of CD151shRNA and CLP which led to elevated levels of intracellular ROS. Conclusion: In the present study we noticed that CD151 gene silencing by shRNA and treatment with CLP have similar effects on reducing the intracellular ROS. This study uncovers the protective activity of CLP against a CD151-mediated oxidative stress-induced cellular damage. Our observations suggest that the anti-stress and anti-inflammation properties of CLP might have implications in cancer and are worth testing in cancer cell lines and tumor cells.</jats:p>
        </jats:abstract>
        <publication_date media_type="online">
          <month>07</month>
          <day>24</day>
          <year>2021</year>
        </publication_date>
        <pages>
          <first_page>162</first_page>
          <last_page>173</last_page>
        </pages>
        <ai:program xmlns:ai="http://www.crossref.org/AccessIndicators.xsd" name="AccessIndicators">
          <ai:license_ref>http://creativecommons.org/licenses/by-nc/4.0</ai:license_ref>
        </ai:program>
        <doi_data>
          <doi>10.32768/abc.202183162-173</doi>
          <resource>https://www.archbreastcancer.com/index.php/abc/article/view/362</resource>
          <collection property="crawler-based">
            <item crawler="iParadigms">
              <resource>https://www.archbreastcancer.com/index.php/abc/article/download/362/494</resource>
            </item>
          </collection>
          <collection property="text-mining">
            <item>
              <resource mime_type="application/pdf">https://www.archbreastcancer.com/index.php/abc/article/download/362/494</resource>
            </item>
          </collection>
        </doi_data>
      </journal_article>
    </journal>
  </body>
</doi_batch>
